[EN] METHODS OF TREATING EPILEPSY USING THE SAME<br/>[FR] PROCÉDÉS DE TRAITEMENT DE L'ÉPILEPSIE À L'AIDE DE CEUX-CI
申请人:TREVENA INC
公开号:WO2021046183A1
公开(公告)日:2021-03-11
The present embodiments are directed, in part, to compounds, or pharmaceutically acceptable salts thereof, or pharmaceutical compositions thereof for modulating the activity of S1P1 receptor and methods of using the same for the treatment of seizures, epilepsy related conditions, epilepsy-related syndrome, and the like as described herein.
[EN] COMBINATIONS OF OPIOID RECEPTOR LIGANDS AND CYTOCHROME P450 INHIBITORS<br/>[FR] COMBINAISONS DE LIGANDS DE RÉCEPTEURS OPIOÏDES ET D'INHIBITEURS DU CYTOCHROME P450
申请人:TREVENA INC
公开号:WO2017106547A1
公开(公告)日:2017-06-22
This application described compounds that can act as opioid receptor ligands, and compositions comprising the compounds and cytochrome P450 inhibitors, which can be used in the treatment of, for example, pain and pain related disorders.
Pyrrolopyrimidine inhibitors of DNA gyrase B (GyrB) and topoisomerase IV (ParE). Part I: Structure guided discovery and optimization of dual targeting agents with potent, broad-spectrum enzymatic activity
作者:Leslie W. Tari、Michael Trzoss、Daniel C. Bensen、Xiaoming Li、Zhiyong Chen、Thanh Lam、Junhu Zhang、Christopher J. Creighton、Mark L. Cunningham、Bryan Kwan、Mark Stidham、Karen J. Shaw、Felice C. Lightstone、Sergio E. Wong、Toan B. Nguyen、Jay Nix、John Finn
DOI:10.1016/j.bmcl.2012.11.032
日期:2013.3
The bacterial topoisomerases DNA gyrase (GyrB) and topoisomerase IV (ParE) are essential enzymes that control the topological state of DNA during replication. The high degree of conservation in the ATP-binding pockets of these enzymes make them appealing targets for broad-spectrum inhibitor development. A pyrrolopyrimidine scaffold was identified from a pharmacophore-based fragment screen with optimization
[EN] JNK INHIBITOR, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF<br/>[FR] INHIBITEUR DE LA JNK, COMPOSITION PHARMACEUTIQUE ASSOCIÉE ET UTILISATION ASSOCIÉE<br/>[ZH] JNK抑制剂、其药物组合物和用途
CONDENSED CYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME
申请人:SAMSUNG DISPLAY CO., LTD.
公开号:US20170155057A1
公开(公告)日:2017-06-01
An organic light-emitting device includes: a first electrode; a second electrode facing the first electrode; and an organic layer between the first electrode and the second electrode, the organic layer including an emission layer, a hole transport region between the first electrode and the emission layer, and an electron transport region between the emission layer and the second electrode, the organic layer including the condensed cyclic compound of Formula 1: